Giuliano Rizzardini - Concepedia

Author

Giuliano Rizzardini

Also Known As

A Gori, A. Lazzarin, Alessandro Capone, Andrea Gori, Anna Gandino, Antonia Nucera, C. Moioli, Carlo Federico Perno, D Bertelli, G Rizzardini

408

Publications

12K

Citations

H-Index

146

Concepts

All Affiliations

Luigi Sacco Hospital University of Milan ASST Fatebenefratelli Sacco University of the Witwatersrand Istituti di Ricovero e Cura a Carattere Scientifico

About

Giuliano Rizzardini is an author at Luigi Sacco Hospital specializing in medicine, hiv, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	48	3.3K
2	Public Health	14	15	1.6K
3	Engineering	3	3	124
4	Health Sciences	3	3	293
5	Social Sciences	2	2	87

Giuliano Rizzardini

139

Publications

8.9K

Citations

H-Index

Page 1

	Year	Citations
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond, New England Journal of Medicine	2020	523
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Piercarlo Sarzi‐Puttini, Valeria Giorgi, Silvia Sirotti, Clinical and Experimental Rheumatology	2020	477
Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study Hans‐Jürgen Stellbrink, Chloe Orkin, José Ramón Arribas, Clinical Infectious Diseases	2010	409
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, The Lancet Hiv/aids CounsellingTreatment And PreventionWeek 48Clinical EpidemiologyClinical Trials	2018	371
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study Edgar T. Overton, Gary Richmond, Giuliano Rizzardini, The Lancet Phase 3BTreatment And PreventionClinical EpidemiologyAntiviral TherapyPharmacotherapy	2020	342
30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study Andrea Giacomelli, Anna Lisa Ridolfo, Laura Milazzo, Pharmacological Research Italian EpidemicInfectious Disease EpidemiologyEpidemiological OutcomeCovid-19 PandemicClinical Epidemiology	2020	264
Retinal findings in patients with COVID-19: Results from the SERPICO-19 study Alessandro Invernizzi, Alessandro Torre, Salvatore Parrulli, EClinicalMedicine	2020	262
Early Impairment of Gut Function and Gut Flora Supporting a Role for Alteration of Gastrointestinal Mucosa in Human Immunodeficiency Virus Pathogenesis Andrea Gori, Camilla Tincati, Giuliano Rizzardini, Journal of Clinical Microbiology DysbiosisImmunologyGastroenterologyPathologyGut Microbiota	2007	235
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection Man‐Fung Yuen, Seng Gee Lim, Robert Pleśniak, New England Journal of Medicine	2022	229
Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status Spinello Antinori, Maria Vittoria Cossu, Anna Lisa Ridolfo, Pharmacological Research Critical Care ManagementCritical Care MedicinePost-treatment Hospitalisation StatusLong CovidIntensive Care Unit	2020	222

Page 1